ARDELYX INC (ARDX)
NASDAQ • Healthcare
Last close at August 10, 2026 at 20:00 UTC
Fundamentals Charts
About ARDELYX INC
Ardelyx, Inc. is a NASDAQ-listed biotechnology company focused on gastrointestinal and cardiorenal conditions, with tenapanor as its marketed product and pipeline anchor. The company generated $407.3 million of revenue in FY2025. Ardelyx changed its name from Nteryx, Inc. and operates from Waltham, Massachusetts.
Analyst Ratings
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings Calendar
Technical Indicators
ARDELYX INC's Technical Indicators Summary
ARDX reads as a clear technical downgrade consistent with a Strong Sell assessment. The trend is decisively negative with ADX near 30 and OBV deeply negative, while the price is below short-, medium- and 200-day averages, indicating broad bearish alignment. Momentum oscillators offer mixed, oversold readings—RSI and stochastic are depressed—yet CCI and MACD remain negative, reflecting persistent selling pressure. Volatility is moderate but not enough to reverse the flow, and pivots are neutral. Technical takeaway: Strong Sell — downtrend confirmed by price, volume and trend strength despite oversold oscillators.
| Indicator | Value |
|---|---|
RSI (14) | 18.69 |
Stochastic %K (14, 3, 3) | 8.79 |
CCI (20) | -330.98 |
WPR (14) | -92.37 |
Momentum (10) | -1.06 |
MFI | 6.80 |
MACD Level (12, 26) | -0.28 |
Bollinger Bands | $4.27 - $5.64 |
ATR (14) | $0.25 (6.31%) |
ADX (14) | 29.85 |
OBV | -10,045,488 |
Classic Pivot Point | $4.06 |
Fibonacci Pivot Point | $4.06 |
Simple Moving Averages | $4.79 - $6.02(5 indicators) |
Exponential Moving Averages | $4.66 - $5.81(5 indicators) |
Get premium market insights delivered directly to your inbox.
Today's Snapshot
ARDX saw stable price action in the last session, ending the day nearly unchanged at 4.00. ARDX lifts IBSRELA revenue guidance to $350–$370M as losses narrow in Q2.
Trading Volume
Above 10d avg 5.7M
10.7M
vs S&P 500 Today
Inline with Market
+0.06%
52-Week Position
Near lows
2.2%
Updated: August 11, 2026 at 12:02 UTC